GlassScriptPhysician profile
Clara Sewell
NPI 1194463901
$5,247.17
in general payments reported to CMS, 2019-2025
32 companies · $2,885 in 2025
The $2,885 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.31 · 2023: $460 · 2024: $1,803 · 2025: $2,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,890.44 |
| Education | $257.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $910.41 | 2024-2025 | Bimzelx |
| Abbvie INC. | $505.11 | 2023-2025 | |
| Genzyme Corporation | $488.41 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $406.72 | 2022-2025 | Odomzo, Yonsa |
| Arcutis Biotherapeutics, INC. | $392.54 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $310.52 | 2023-2025 | Tremfya, Imbruvica, Darzalex |
| Dermavant Sciences, INC. | $267.83 | 2024 | Vtama |
| Amgen INC. | $183.59 | 2022-2025 | Blincyto, Kyprolis, Evenity |
| Leo Pharma INC. | $183.04 | 2025 | Anzupgo, Adbry |
| Incyte Corporation | $170.05 | 2024-2025 | Opzelura |
| Organon LLC | $166.81 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $150.76 | 2025 | Aklief, Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $141.76 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $134.85 | 2025 | Dupixent |
| Lilly USA, LLC | $122.58 | 2025 | Ebglyss |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.07 | 2022-2024 | |
| Pfizer INC. | $108.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $80.60 | 2023-2025 | |
| Exelixis INC. | $57.74 | 2022-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $53.56 | 2023 | Xpovio |
| Eisai INC. | $39.75 | 2023 | |
| Seagen INC. | $38.32 | 2023 | Adcetris, Padcev |
| Merck Sharp & Dohme LLC | $33.02 | 2023 | Keytruda |
| Sobi, INC | $31.91 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2024 | |
| G1 Therapeutics, INC. | $23.31 | 2023 | Cosela |
| Tolmar, INC. | $23.12 | 2023 | |
| Celltrion USA INC. | $20.14 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $20.03 | 2024 | Enhertu |
| Digestive Care, INC. | $16.98 | 2025 | Pertzye |
| Kyowa Kirin, INC. | $16.35 | 2025 | |
| Blueprint Medicines Corporation | $12.75 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Sewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.